三个P：腮腺、程序性死亡受体1配体（PD-L1）和帕博利珠单抗。
The Three P's: Parotid, PD-L1, and Pembrolizumab.
作者信息
Wiggins Amanda, Arter Zhaohui, Kerns Tamie
机构信息
Tripler Army Medical Center, 1 Jarrett White Road, DHCK-DM, Honolulu, HI 96859, USA.
出版信息
Case Rep Oncol Med. 2019 Jun 11;2019:2305315. doi: 10.1155/2019/2305315. eCollection 2019.
Abstract
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
摘要
我们报告了一例复发性、铂类难治性腮腺未分化癌患者，该患者接受了检查点抑制剂帕博利珠单抗治疗，并对治疗取得了完全缓解。我们回顾了检查点抑制剂在腮腺未分化癌中应用的文献。
Zotero 插件